← All trials
NCT06444620
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 22, 2024
- Primary completion
- Jul 22, 2025
- Completion date
- Jul 22, 2026
- First posted
- Jun 5, 2024
- Last posted
- Oct 29, 2024
- Enrollment
- 240
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of NairobiLead sponsor
- University of NairobiSponsor investigator
- University of NairobiOfficial
- ViiV HealthcareCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.